A non-functional galanin receptor-2 in a multiple sclerosis patient.


Journal

The pharmacogenomics journal
ISSN: 1473-1150
Titre abrégé: Pharmacogenomics J
Pays: United States
ID NLM: 101083949

Informations de publication

Date de publication:
02 2019
Historique:
received: 26 11 2017
accepted: 14 05 2018
revised: 26 04 2018
pubmed: 23 8 2018
medline: 21 3 2019
entrez: 23 8 2018
Statut: ppublish

Résumé

Multiple Sclerosis (MS) is an inflammatory neurodegenerative disease that affects approximately 2.5 million people globally. Even though the etiology of MS remains unknown, it is accepted that it involves a combination of genetic alterations and environmental factors. Here, after performing whole exome sequencing, we found a MS patient harboring a rare and homozygous single nucleotide variant (SNV; rs61745847) of the G-protein coupled receptor (GPCR) galanin-receptor 2 (GALR2) that alters an important amino acid in the TM6 molecular toggle switch region (W249L). Nuclear magnetic resonance imaging showed that the hypothalamus (an area rich in GALR2) of this patient exhibited an important volumetric reduction leading to an enlarged third ventricle. Ex vivo experiments with patient-derived blood cells (AKT phosphorylation), as well as studies in recombinant cell lines expressing the human GALR2 (calcium mobilization and NFAT mediated gene transcription), showed that galanin (GAL) was unable to stimulate cell signaling in cells expressing the variant GALR2 allele. Live cell confocal microscopy showed that the GALR2 mutant receptor was primarily localized to intracellular endosomes. We conclude that the W249L SNV is likely to abrogate GAL-mediated signaling through GALR2 due to the spontaneous internalization of this receptor in this patient. Although this homozygous SNV was rare in our MS cohort (1:262 cases), our findings raise the potential importance of impaired neuroregenerative pathways in the pathogenesis of MS, warrant future studies into the relevance of the GAL/GALR2 axis in MS and further suggest the activation of GALR2 as a potential therapeutic route for this disease.

Identifiants

pubmed: 30131588
doi: 10.1038/s41397-018-0032-6
pii: 10.1038/s41397-018-0032-6
doi:

Substances chimiques

Receptor, Galanin, Type 2 0
Galanin 88813-36-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

72-82

Subventions

Organisme : Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development)
ID : 480138/2013-3
Pays : International
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo Research Foundation)
ID : 2015/07925-5
Pays : International
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo Research Foundation)
ID : 2016/06488-3
Pays : International
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Federal Agency for the Support and Evaluation of Graduate Education)
ID : 23038.007775/2014-98
Pays : International
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Federal Agency for the Support and Evaluation of Graduate Education)
ID : 7350-15-5
Pays : International

Auteurs

Sheila Garcia-Rosa (S)

Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.

Daniela Bb Trivella (DB)

Brazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP, Brazil.
CAPES-University of Nottingham Programme in Drug Discovery, Queen's Medical Centre University of Nottingham, Nottingham, NG7 2UH, United Kingdom.
Cell Signalling Research Group, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.

Vanessa D Marques (VD)

Department of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Rodolfo B Serafim (RB)

Department of Cellular and Molecular Biology, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

José Gc Pereira (JG)

Brazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP, Brazil.

Julio Cc Lorenzi (JC)

Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Greice A Molfetta (GA)

Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Paulo P Christo (PP)

Curso de Pós-Graduação, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil.

Guilherme S Olival (GS)

Neurosciences Research Group, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.

Vania Bt Marchitto (VB)

Neurosciences Research Group, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.

Doralina G Brum (DG)

Department of Neurology, Psychology and Psychiatry, School of Medicine of Botucatu, University of State of São Paulo (UNESP), Botucatu, SP, Brazil.

Thais S Sabedot (TS)

Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Houtan Noushmehr (H)

Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Alessandro S Farias (AS)

Neuroimmunology Unit, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.

Leonilda Mb Santos (LM)

Neuroimmunology Unit, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.

José A Nogueira-Machado (JA)

Curso de Pós-Graduação, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil.

Jorge Es Souza (JE)

Instituto Metrópole Digital, Federal University of Rio Grande do Norte, Natal, RN, Brazil.

Camila M Romano (CM)

Lab. Virology (LIM52), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil.

Rodrigo M Conde (RM)

Department of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Antonio C Santos (AC)

Department of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Carlos T Guerreiro (CT)

Department of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.

Willem H Schreuder (WH)

Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.

Frederico O Gleber-Netto (FO)

Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.

Maria Amorim (M)

Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.

Renan Valieris (R)

Laboratory of Bioinformatics and Computational Biology, AC Camargo Cancer Center, Sao Paulo, Brazil.

Israel Tojal da Silva (ITD)

Laboratory of Bioinformatics and Computational Biology, AC Camargo Cancer Center, Sao Paulo, Brazil.

Wilson A Silva (WA)

Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Center for Medical Genomics at HCFMRP, Universidade de Sao Paulo (USP), Ribeirão Preto, Brazil.

Diana N Nunes (DN)

Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.

Paulo Sl Oliveira (PS)

Brazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP, Brazil.

Valeria Valente (V)

School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil.

Maria Augusta Arruda (MA)

CAPES-University of Nottingham Programme in Drug Discovery, Queen's Medical Centre University of Nottingham, Nottingham, NG7 2UH, United Kingdom.
Cell Signalling Research Group, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Farmanguinhos, Fiocruz, Rio de Janeiro, Brazil.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Nottingham, United Kingdom.

Stephen J Hill (SJ)

Cell Signalling Research Group, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom. Steve.Hill@nottingham.ac.uk.
Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Nottingham, United Kingdom. Steve.Hill@nottingham.ac.uk.

Amilton A Barreira (AA)

Department of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil. aabarrei@fmrp.usp.br.

Emmanuel Dias-Neto (E)

Lab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil. emmanuel@accamargo.org.br.
Lab. of Neurosciences (LIM27), Institute of Psychiatry, School of Medicine, University of São Paulo USP, São Paulo, SP, Brazil. emmanuel@accamargo.org.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH